Introduction
Hilar cholangiocarcinoma (HCCA) involving the hepatic duct confluence, or Klatskin's tumour, accounts for approximately 60-70% of all cholangiocarcinomas. Since Klatskin's first report of this tumour, 1 many subsequent publications have dealt with its diagnosis, staging, surgical management and prognosis. The only curative therapy has remained margin-negative (R0) resection. Prognosis has improved significantly, with 5-year survival rates of 25-35% 2-5 after resection, usually encompassing extended liver resection. Although morbidity and mortality rates have dropped in recent years, reported mortality rates still range from 9% to 15%. [2] [3] [4] [5] Therefore, accurate tumour staging and assessment of resectability are crucial in the selection of patients in whom curative surgery is possible. In addition, the differentiation of HCCA from benign lesions that mimic malignancies has proven a difficult diagnostic problem. Several institutional reports have found 10-15% of patients suspected for HCCA to have been misdiagnosed on microscopic examination of the resection specimen. 6, 7 Different imaging techniques are used in the staging of HCCA. Although the quality of imaging has improved in recent years, a significant number of patients are found to be unresectable during laparotomy, despite extensive preoperative work. 8 Of the patients who are surgically explored, only 40-50% are ultimately resectable 9 and R0 resection is reportedly achieved in 19-80% of resected patients. [2] [3] [4] [5] Hence, after two decades of experience and despite all the improvements in diagnostic imaging, the correct diagnosis and staging of HCCA remain challenging.
As malignant cells usually show increased glucose metabolism, positron emission tomography (PET) imaging with the tracer [ F-FDG; FDG-PET) has been developed to detect primary tumours and distant metastases. This technique has been shown to be highly sensitive and specific for the detection of distant metastases from various primary tumours. More recently, improved computing abilities and technology have enabled FDG-PET to be fused with computed tomography (CT) to add precision anatomic and functional localization. The value of PET/CT has been proven in the detection of unknown primary tumours 10 and in the detection of distant metastases in the staging of pancreatic, 11 oesophageal 12 and colorectal 13, 14 cancer. The potential role of FDG-PET/CT in cholangiocarcinoma and, particularly, HCCA has not been well established.
The purpose of this study was to evaluate in retrospect the additional value of FDG-PET/CT in the diagnosis and staging of HCCA in our institution.
Materials and methods

Patients
Thirty patients who underwent PET/CT followed by intraoperative assessment and histological confirmation of HCCA between February 2006 and August 2009 were included in this study. These patients were among a consecutive series referred to the Academic Medical Centre (AMC), University of Amsterdam, a tertiary referral centre, with the presumptive diagnosis of HCCA. The characteristics of these patients are shown in Table 1 . Their median age was 62 years (range: 36-77 years). Fourteen patients (47%) were men and 16 (53%) were women.
The preoperative workup of our HCCA patients prior to explorative laparotomy included a contrast-enhanced CT, transabdominal ultrasound with Doppler imaging, direct cholangiography when available, and diagnostic laparoscopy. The PET-CT method was added as a final non-invasive tool to exclude unresectability.
Magnetic resonance imaging (MRI) was also performed in 34% of patients. The Bismuth-Corlette classification was used to describe the proximal extent of the tumour preoperatively. The definitive preoperative classification is shown in Table 1 .
All patients underwent endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiodrainage (PTCD) for diagnosis and subsequent biliary drainage approximately 6 weeks prior to surgery. Preoperative radiotherapy (3 ¥ 3.5 Gy) was given to prevent the implantation of metastases by ERCP or PTCD. 15 The size and function of the future remnant liver were assessed preoperatively by CT volumetry 16 and 99m Tcmebrofenin hepatobiliary scintigraphy. 17 Portal vein embolization was performed in two patients with insufficient future remnant liver volume to induce hypertrophy and to reduce the risk of postoperative liver failure. 20 Whole-body coverage was performed with an axial scan ranging from the base of the skull to the upper thighs. Low-dose CT images were acquired in spiral mode at 670 mAs, 120 kV, a slice width of 5 mm and a table feed of 8 mm/gantry rotation. Images were reconstructed in 2.4-mm increments. All patients were scanned using a limited breath-hold technique to avoid the misregistration of images in the area of the diaphragm. The time to acquire a single bed position was set to 3 min. Images obtained using PET were corrected for attenuation based on the CT data.
Computed tomography and PET images acquired by this combined imaging system were viewed in separate and fused modes using the fusion software Hybrid Viewer (Hermes Medical Solutions AB, Stockholm, Sweden) by a board-certified radiologist and a board-certified nuclear medicine doctor in consensus. For this retrospective analysis, images were re-evaluated by an experienced nuclear medicine doctor (RJB) who was trained in multimodal imaging and who was unaware of findings obtained using other conventional modes of imaging. Tumour staging using the PET/CT images was scored according to the revised Union for International Cancer Control (UICC) criteria (6th edition) for extrahepatic bile duct cancer. 19 These findings were compared with intraoperative findings and the results of pathological examination. The histology reports were used as the reference standard for the diagnosis of the primary tumour, lymph node involvement and distant metastases. Images were evaluated qualitatively for regions of focally increased glucose metabolism, as well as quantitatively by determining the standardized uptake values (SUVs). An increase in glucose uptake above the levels in the surrounding tissue on qualitative analysis was considered suspicious for malignancy. Lymph node and distant metastases with increased glucose utilization were diagnosed positive for metastatic spread, even if their short axis diameter measured <10 mm.
Surgical procedures
Diagnostic laparoscopy, exploratory laparotomy and subsequent tumour resection were performed by a surgical team specializing in hepatobiliary surgery. During laparotomy, the abdomen was inspected for lymph node involvement distant to the liver hilum, peritoneal seeding and other extrahepatic metastases. Suspicious lesions were excised or biopsied and analysed by frozen-section histology. In cases of extrahepatic metastases, no further surgical intervention was performed. Radical resection of HCCA encompassed the excision of the liver hilum en-bloc with (extended) hemihepatectomy including the caudate lobe, excision of the portal vein bifurcation when involved and complete lymphadenectomy of the hepatoduodenal ligament. Massive involvement of the main trunk of the portal vein and/or hepatic artery was considered a contraindication for resection. For biliary reconstruction, end-to-side anastomoses of the segmental ducts and a Roux-en-Y jejeunal loop were constructed. 3 In most patients with resectable tumours, lymph node status was evaluated by dissecting the hepatoduodenal ligament and excising the lymph nodes along the common hepatic artery and coeliac axis. In patients who were found to be unresectable during diagnostic laparoscopy or explorative laparotomy, not all lymph nodes were sampled.
Statistical analysis
Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values and accuracy were calculated for the staging of primary tumours, regional lymph node and distant metastases.
The SUV was expressed as the mean Ϯ standard error. Independent-samples t-test was used to test the predictive value of the SUV for American Joint Committee on Cancer (AJCC) cancer stage, presence of positive lymph nodes, presence of distant metastases, resectability and benign disease. P-values of <0.05 were considered statistically significant. Data were analysed using spss Version 16.0 (SPSS, Inc., Chicago, IL, USA).
Results
Clinicopathological characteristics
Of the 30 patients included in this study, resection was undertaken in 21 (70%). In 27 patients (90%) a biliary plastic stent had been placed prior to the PET/CT. Hilar resection in combination with (extended) hemihepatectomy was performed in 17 patients (81% of all resections). In four of the 21 resected patients (19%), hilar resection was performed locally without formal liver resection. Final histology showed benign disease in four patients (19%) characterized as IgG-4-associated sclerosing cholangitis (n = 2), intraductal papillary mucinous tumour (n = 1) and chronic inflammation (n = 1). In the remaining 17 patients with confirmed HCCA, a microscopically complete (R0) resection was achieved in 15 patients (88%).
18
F-FDG-PET/CT accuracy for primary tumour, lymph node and distant metastases Twenty-three of 26 (sensitivity: 88%) patients with confirmed HCCA were correctly identified when PET/CT showed FDG uptake in the hilar region, which was also visible on the nonattenuation corrected images. No lesions were correctly identified as benign on qualitative evaluation because the benign lesions also showed uptake of FDG. Overall PPV, NPV and accuracy rates for primary tumour detection, presence of positive lymph nodes and distant metastases are shown in Table 2 .
Overall, pathological examination showed positive lymph nodes in six of 30 patients (20%). Four of these were correctly identified (sensitivity: 66%) on PET/CT. However, lymph node status was not assessed in three patients scored as N1 on PET/CT because other findings during surgery precluded resection. As Table 3 shows, PET/CT seemed to have a higher sensitivity for the detection of positive lymph nodes than regular CT, although an adequate statistical comparison was not possible because of the small numbers involved. Lymph nodes were not further defined with respect to localization (within or beyond the hepatoduodenal ligament), also because of the small size of the sample.
Unknown metastases after initial staging were apparent in six patients and correctly identified in only two. None of the four patients with peritoneal deposits were diagnosed on the basis of PET/CT. Of three patients with liver metastases, two were correctly detected by PET/CT. One of these patients was preoperatively biopsied and a liver metastasis was histologically confirmed and laparotomy avoided. In the other patient with suspected liver metastasis on CT, a biopsy was inconclusive. Consequently, the patient was explored and the metastasis confirmed. PET/CT missed a liver metastasis in the third patient harbouring a small subcapsular liver lesion. In one patient a liver metastasis was suspected on the basis of PET/CT, but final biopsy and histology showed an inflammatory infiltrate. This represented the site of a biopsy during diagnostic laparoscopy which had proven to be a chronically dilated bile duct and was subsequently over-sutured.
Incidental PET/CT positive findings in two patients showed a Whartin tumour which required further evaluation in one and an adrenal cyst and diverticulitis without further therapeutic consequences in the other.
SUV max
Standardized uptake values and corresponding clinicopathological characteristics are depicted in Table 4 . The SUV showed no significant predictive power for AJCC cancer stage, presence of positive lymph nodes or resectability, but was significantly higher in patients diagnosed with distant metastases (P = 0.02).
In addition, the SUV was lower in benign lesions, although the difference was not statistically significant in this small group of patients (P = 0.09).
Potential impact on management
If FDG-PET/CT had been used to restage patients after initial staging including diagnostic laparoscopy, it would have changed the management strategy applied in three of the 30 patients (10%). Laparotomy might have been avoided in two patients with liver metastases and additional imaging and treatment for a Whartin tumour were required in one patient. Because of its uncertain accuracy regarding lymph node staging, FDG-PET/CT would not have changed the management of patients with nodal disease. However, this may change when the accuracy of PET/CT in lymph node staging is better defined.
Discussion
In this study of 30 patients with suspected HCCA considered for curative surgery, the primary tumour was 18 [21] [22] [23] [24] [25] However, as Table 5 shows, most series have pooled HCCA patients with those with other cholangiocarcinomas, including gallbladder and intrahepatic cholangiocarcinomas. In these studies, patients with HCCA often comprise only a minority of all included patients. Thus, the differences in tumour biology, pattern and incidence of metastases or the different types of cholangiocarcinoma make the outcomes of these studies difficult to interpret. For example, gallbladder cancer is known for its higher incidence of distant metastases.
F-FDG-positive in
The 18 F-FDG-positivity in 88% of patients found in this study is high in comparison with rates reported elsewhere, as shown in Table 5 . However, this is of little relevance because our patients were already diagnosed with HCCA based on clinical presentation, imaging studies and sometimes (brush) cytology. Moreover, all benign lesions were also FDG-positive. Nonetheless, 18 F-FDGpositivity enables SUV measurements, which potentially facilitate the differentiation of benign and malignant lesions.
The specificity found in this study to differentiate benign from malignant lesions was low because all benign inflammatory lesions showed increased FDG uptake and no true negative results were found. This is compatible with the fact that most benign lesions in the hilar liver region have an inflammatory origin, 26 a characteristic that is also known for increased metabolic activity and FDG-PET-positivity. We therefore believe that qualitative interpretation of PET/CT alone does not discriminate between benign and malignant lesions in the hilar region, but that calculation of the SUV may be of potential value in differentiating these lesions, as shown in this study.
The detection of positive lymph nodes on CT images is primarily based on lymph node size. Nodes of >10 mm in the smallest diameter are suspicious. The sensitivity and specificity of this size-based lymph node characterization are known to be minimal and its clinical usefulness therefore remains limited. The addition of 18 F-FDG-PET/CT might potentially improve the accuracy of lymph node staging. In this study, the accuracy of PET/CT for lymph node staging seemed better than that of CT alone. The accuracy of PET/CT may have been even better because nodal status was not assessed in three patients with PET-positive lymph nodes because these patients were not resectable. Clearly, numbers in this study are too small to allow for adequate statistical evaluation and care must be taken not to draw conclusions on these data. Lee et al. found statistical significance only for specificity in favour of PET/CT for lymph node staging in their relatively large series of extrahepatic cholangiocarcinomas. 23 Hence, larger studies are needed to draw definitive conclusions regarding the value of PET/CT in the assessment of lymph node involvement.
The sensitivity of 33% for the detection of distant metastases in this study was rather low, especially as this facility has been thought to be the main advantage of PET/CT. However, the metastases found had not been detected in the initial staging, including diagnostic laparoscopy. The results were also inferior to those of other studies, which reported detection rates of distant metastases of 56-100%. [21] [22] [23] [24] [25] These differences in rates may possibly be explained by two factors. Firstly, distant metastases in our study included mostly peritoneal metastases (66%), which are hard to detect in PET/CT or other imaging modalities. Secondly, this study included a selected group of patients who were considered to be eligible for curative surgery after exhaustive preoperative workup, including diagnostic laparoscopy in all cases. Consequently, the incidence of distant metastases was low and only metastases which were small and difficult to diagnose were featured in this study. Both PET/CT and diagnostic laparoscopy are performed in order to exclude metastases. Given the invasiveness of diagnostic laparoscopy and its accompanying morbidity and length of hospital stay, the potential contribution of PET/CT to reducing the number of patients undergoing this procedure may be beneficial.
The calculated SUVs for the primary tumour and metastatic lesions showed promising results. Patients with distant metastases had significantly higher SUVs for the primary tumour. This may be secondary to the higher tumour metabolism of more aggressive Patients with benign disease seemed to have lower SUVs for the primary lesion, although significance was not reached in this small patient group. The latter findings were also reported by Reinhardt et al., who determined an SUV of 3.6 as an ideal cutoff point to discriminate between benign disease and cholangiocarcinoma. 27 As absolute SUVs are known to vary between centres, local recalibration is necessary to enable interpretation of these results. 20 There are several limitations to this retrospective study, which aimed to assess the additional value of PET/CT as a final noninvasive tool to help avoid unnecessary surgery in inoperable patients. Because of the rarity of the disease, data were obtained from a small group of patients in a retrospective manner, which has inherent methodological drawbacks. Most HCCA patients are referred to our tertiary hospital with a stent already in situ.
The insertion of such stents is frequently followed by an inflammatory reaction, which hampers the optimal interpretation of PET/CT images. Therefore, we believe PET/CT should optimally be performed prior to any invasive technique, including stent placement and laparoscopy. Moreover, benign lesions of inflammatory origin mimicking malignancy occur in this patient group and are a known source of false positive PET/CT readings. Hence, any conclusions must be drawn with care. A prospective study on a larger scale should be conducted to confirm these results and to further define the role of PET/CT in the staging of patients with HCCA.
Finally, by contrast with earlier studies, 21, [23] [24] [25] 28 the yield of PET/CT after intensive staging was rather disappointing, given its low sensitivity for detecting metastases and benign lesions, which resulted in false positive PET/CT readings. This probably reflects both the extensive staging carried out prior to PET/CT and the high proportion of patients with peritoneal metastases. It is possible that the impact of PET/CT will improve when the technique is used earlier in the staging process, especially before invasive procedures such as diagnostic laparoscopy are undertaken. By contrast, SUVs showed promising results for predicting metastases. Further research is warranted to confirm these results and to identify certain cut-off values to make the assessment of SUVs useful in a clinical setting (i.e. for selecting patients for diagnostic laparoscopy and possibly neoadjuvant therapy).
In conclusion, after conventional staging including diagnostic laparoscopy, the additional value of PET/CT is limited. This somewhat disappointing finding may possibly reflect a context in which extensive staging studies have been carried out prior to PET/CT, whereas the yield of PET/CT may be higher if it is conducted before any invasive procedures. In addition to qualitative (visual) interpretation of images, SUV calculation potentially predicts patients with distant metastases and may differentiate between HCCA and benign lesions that mimic malignancies.
